MY168643A - Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism - Google Patents
Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatismInfo
- Publication number
- MY168643A MY168643A MYPI2014000825A MYPI2014000825A MY168643A MY 168643 A MY168643 A MY 168643A MY PI2014000825 A MYPI2014000825 A MY PI2014000825A MY PI2014000825 A MYPI2014000825 A MY PI2014000825A MY 168643 A MY168643 A MY 168643A
- Authority
- MY
- Malaysia
- Prior art keywords
- compositions
- methods
- irregular astigmatism
- nsaid
- cox
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 206010020675 Hypermetropia Diseases 0.000 title abstract 2
- 201000009310 astigmatism Diseases 0.000 title abstract 2
- 201000006318 hyperopia Diseases 0.000 title abstract 2
- 230000004305 hyperopia Effects 0.000 title abstract 2
- 201000000766 irregular astigmatism Diseases 0.000 title abstract 2
- 201000010041 presbyopia Diseases 0.000 title abstract 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 4
- 239000000556 agonist Substances 0.000 abstract 3
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 abstract 2
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000001713 cholinergic effect Effects 0.000 abstract 2
- 125000002636 imidazolinyl group Chemical group 0.000 abstract 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 102000000166 Muscarinic acetylcholine receptor M3 Human genes 0.000 abstract 1
- 108050008508 Muscarinic acetylcholine receptor M3 Proteins 0.000 abstract 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 abstract 1
- 230000002350 accommodative effect Effects 0.000 abstract 1
- 201000006327 accommodative esotropia Diseases 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 210000000695 crystalline len Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229960001416 pilocarpine Drugs 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161536921P | 2011-09-20 | 2011-09-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY168643A true MY168643A (en) | 2018-11-27 |
Family
ID=47522725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2014000825A MY168643A (en) | 2011-09-20 | 2012-09-19 | Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism |
Country Status (23)
| Country | Link |
|---|---|
| US (7) | US9579308B2 (enExample) |
| EP (3) | EP4272743A3 (enExample) |
| JP (1) | JP6141850B2 (enExample) |
| KR (1) | KR102017916B1 (enExample) |
| CN (1) | CN104093404B (enExample) |
| AU (2) | AU2012311239B2 (enExample) |
| BR (1) | BR112014006607A2 (enExample) |
| CA (2) | CA3049795A1 (enExample) |
| CL (1) | CL2014000689A1 (enExample) |
| CO (1) | CO7000769A2 (enExample) |
| DK (1) | DK2758047T3 (enExample) |
| ES (1) | ES2715296T3 (enExample) |
| IL (1) | IL231631B (enExample) |
| IN (1) | IN2014CN02961A (enExample) |
| MX (1) | MX357635B (enExample) |
| MY (1) | MY168643A (enExample) |
| PH (1) | PH12014500636B1 (enExample) |
| RU (1) | RU2630968C2 (enExample) |
| SG (1) | SG11201400828RA (enExample) |
| TR (1) | TR201903465T4 (enExample) |
| UA (1) | UA113525C2 (enExample) |
| WO (1) | WO2013041967A2 (enExample) |
| ZA (1) | ZA201402049B (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| US12478503B2 (en) | 2009-05-18 | 2025-11-25 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| IN2014CN02961A (enExample) | 2011-09-20 | 2015-07-03 | Altavista Inst De Invest Medica S A S | |
| TWI588560B (zh) | 2012-04-05 | 2017-06-21 | 布萊恩荷登視覺協會 | 用於屈光不正之鏡片、裝置、方法及系統 |
| US10507245B2 (en) | 2012-07-19 | 2019-12-17 | Luis Felipe Vejarano Restrepo | Ophthalmic formulation and method for ameliorating presbyopia |
| US9201250B2 (en) | 2012-10-17 | 2015-12-01 | Brien Holden Vision Institute | Lenses, devices, methods and systems for refractive error |
| CA2887655C (en) | 2012-10-17 | 2021-11-02 | Brien Holden Vision Institute | Lenses, devices, methods and systems for refractive error |
| US10064818B2 (en) | 2013-08-28 | 2018-09-04 | Presbyopia Therapies, LLC | Compositions and methods for the treatment of presbyopia |
| US9844537B2 (en) | 2013-08-28 | 2017-12-19 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| US9320709B2 (en) | 2013-08-28 | 2016-04-26 | Presbyopia Therapies Llc | Storage stable compositions and methods for the treatment of refractive errors of the eye |
| US9089562B2 (en) | 2013-08-28 | 2015-07-28 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| US10617763B2 (en) | 2013-08-28 | 2020-04-14 | Presbyopia Therapies, LLC | Compositions and methods for the treatment of presbyopia |
| US9314427B2 (en) | 2013-08-28 | 2016-04-19 | Presbyopia Therapies Llc | Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye |
| US9833441B2 (en) | 2013-08-28 | 2017-12-05 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| US9968594B2 (en) | 2013-08-28 | 2018-05-15 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| US10307408B2 (en) | 2013-08-28 | 2019-06-04 | Presbyopia Therapies, LLC | Contact lens compositions and methods for the treatment of presbyopia |
| US11179327B2 (en) | 2013-08-28 | 2021-11-23 | Lenz Therapeutics, Inc. | Compositions and methods for the treatment of presbyopia |
| ES2538551B1 (es) * | 2013-12-20 | 2016-01-13 | Eurocanarias Oftalmológica, Sl | Composición Oftálmica para la corrección de la presbicia |
| EP3244851B1 (en) | 2015-01-12 | 2024-10-16 | Bausch + Lomb Ireland Limited | Micro-droplet delivery device |
| CN104622800A (zh) * | 2015-02-03 | 2015-05-20 | 吉林修正药业新药开发有限公司 | 苄达赖氨酸滴眼液及制备方法 |
| KR20170135862A (ko) | 2015-04-10 | 2017-12-08 | 켄달리온 테라퓨틱스 인코포레이티드 | 교체 가능한 앰플을 갖는 압전 디스펜서 |
| CA2987787C (en) | 2015-06-18 | 2023-06-27 | Presbyopia Therapies, LLC | Compositions for the improvement of distance vision and the treatment of refractive errors of the eye |
| US12653779B2 (en) | 2015-06-18 | 2026-06-16 | Lenz Therapeutics Operations, Inc. | Compositions and methods for the treatment of presbyopia |
| US20190000808A1 (en) * | 2015-07-13 | 2019-01-03 | Allergan, Inc. | Composition and methods for the treatment of blephopharoptosis |
| CH711969A2 (it) * | 2015-12-29 | 2017-06-30 | Pinelli Roberto | Composizione per il trattamento della presbiopia. |
| KR102472774B1 (ko) * | 2016-08-19 | 2022-11-30 | 오라시스 파마슈티칼스 엘티디. | 안과용 약학 조성물 및 이와 관련된 용도 |
| CN109906120A (zh) | 2017-01-20 | 2019-06-18 | 科达莱昂治疗公司 | 压电流体分配器 |
| WO2019113483A1 (en) | 2017-12-08 | 2019-06-13 | Kedalion Therapeutics, Inc. | Fluid delivery alignment system |
| WO2019200121A1 (en) * | 2018-04-12 | 2019-10-17 | Kedalion Therapeutics, Inc. | Topical ocular delivery methods and devices for use in the same |
| US12350194B1 (en) * | 2018-04-12 | 2025-07-08 | Bausch + Lomb Ireland Limited | Topical ocular delivery of fluids with controlled mass dosing and wireless communication |
| JP6946575B2 (ja) | 2018-04-24 | 2021-10-06 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | 眼の状態の治療のためのピロカルピン塩酸塩の使用 |
| EP3817696B8 (en) | 2018-07-03 | 2024-12-11 | Bausch + Lomb Ireland Limited | Topical ocular delivery devices |
| US20210251970A1 (en) | 2018-10-10 | 2021-08-19 | Presbyopia Therapies Inc | Compositions and methods for storage stable ophthalmic drugs |
| BR112021006618B1 (pt) | 2018-10-10 | 2022-09-27 | Presbyopia Therapies, Inc | Composições e métodos para o tratamento da presbiopia |
| KR20210135269A (ko) * | 2019-03-04 | 2021-11-12 | 아이노비아 인코포레이티드 | 필로카르핀을 눈에 액적의 마이크로-용량 스트림으로 전달하기 위한 방법 및 장치 |
| US11679028B2 (en) | 2019-03-06 | 2023-06-20 | Novartis Ag | Multi-dose ocular fluid delivery system |
| US12097145B2 (en) | 2019-03-06 | 2024-09-24 | Bausch + Lomb Ireland Limited | Vented multi-dose ocular fluid delivery system |
| WO2020252061A1 (en) * | 2019-06-10 | 2020-12-17 | Visus Therapeutics, Inc. | Carabachol-bromonidine formulation to enhance anti-presbyopia effects |
| EP3980017A4 (en) * | 2019-06-10 | 2023-06-28 | Visus Therapeutics, Inc. | Using parasympathomimetic drugs alone or, in combination with one or more alpha agonists in pseudophakic patients, to create multi-focality |
| US12496218B1 (en) | 2019-11-12 | 2025-12-16 | Bausch + Lomb Ireland Limited | Fractionated topical ocular drug delivery methods and devices for use in the same |
| CA3180199A1 (en) | 2020-04-17 | 2021-10-21 | Yehuda Ivri | Hydrodynamically actuated preservative free dispensing system |
| US11938057B2 (en) | 2020-04-17 | 2024-03-26 | Bausch + Lomb Ireland Limited | Hydrodynamically actuated preservative free dispensing system |
| US12290472B2 (en) | 2020-04-17 | 2025-05-06 | Bausch + Lomb Ireland Limited | Hydrodynamically actuated preservative free dispensing system |
| EP4120973B1 (en) | 2020-04-17 | 2026-06-10 | Bausch + Lomb Ireland Limited | Hydrodynamically actuated preservative free dispensing system having a collapsible liquid reservoir |
| BR112022026911A2 (pt) * | 2020-09-11 | 2023-03-28 | Intratus Nevada Inc | Composições e métodos para tratar presbiopia, hipermetropia, astigmatismo, diminuição da estereopsia e diminuição da sensibilidade ao contraste |
| MX394625B (es) * | 2020-11-12 | 2025-03-24 | Cesar Alejandro Sanchez Galeana | Composicion oftalmologica sinergica en dosis de baja concentracion eficaz en la prevencion, control y erradicacion de la presbicia |
| WO2022182740A1 (en) | 2021-02-24 | 2022-09-01 | Ocular Therapeutix, Inc. | Intracanalicular depot inserter device |
| WO2023086878A1 (en) | 2021-11-10 | 2023-05-19 | Visus Therapeutics, Inc. | Carbachol formulations to enhance anti-presbyopia effects |
| WO2023091439A1 (en) | 2021-11-17 | 2023-05-25 | Lenz Therapeutics, Inc. | Aceclidine derivatives, compositions thereof and methods of use thereof |
| US11648247B1 (en) | 2021-12-16 | 2023-05-16 | Lenz Therapeutics, Inc. | Compositions and methods for the treatment of presbyopia |
| US20250127760A1 (en) * | 2021-12-28 | 2025-04-24 | Shenyang Xingqi Pharmaceutical Co., Ltd. | Composition and use thereof in preparation of medicament for treating presbyopia |
| US20230277521A1 (en) * | 2022-03-07 | 2023-09-07 | Harrow Ip, Llc | Extended-release pharmaceutical compositions for treating eye conditions |
| WO2024220441A1 (en) * | 2023-04-17 | 2024-10-24 | Lenz Therapeutics Operations, Inc. | Methods for the treatment of presbyopia |
| CN117414333A (zh) * | 2023-11-30 | 2024-01-19 | 南京正科医药股份有限公司 | 盐酸毛果芸香碱滴眼液及其制备方法 |
| US12414942B1 (en) | 2024-03-15 | 2025-09-16 | Lenz Therapeutics Operations, Inc. | Compositions, methods, and systems for treating presbyopia |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3670087A (en) | 1970-10-16 | 1972-06-13 | Miles Lab | Method of lowering intraocular pressure |
| US5122522A (en) | 1989-06-21 | 1992-06-16 | The Trustees Of The University Of Pennsylvania | Treatment and control of ocular development |
| US5055467A (en) | 1989-11-13 | 1991-10-08 | Allergan, Inc. | Pharmaceutical epinephrine-pilocarpine compounds |
| US5776916A (en) | 1990-07-10 | 1998-07-07 | Gramer; Eugen | Medicament for reducing the intraocular pressure |
| US5459133A (en) | 1992-06-05 | 1995-10-17 | Telor Ophthalmic Pharmaceuticals, Inc. | Methods and products for treating presbyopia |
| JPH07508751A (ja) | 1992-07-02 | 1995-09-28 | テラー・オフサルミック・ファーマシューティカルズ・インコーポレーテッド | 老視治療のための方法および生産品 |
| SE512871C2 (sv) | 1992-08-20 | 2000-05-29 | Santen Oy | Oftalmologisk beredning innehållande pilokarpin och ytterligare medel för behandling av okular hypertension |
| US5422116A (en) | 1994-02-18 | 1995-06-06 | Ciba-Geigy Corporation | Liquid ophthalmic sustained release delivery system |
| US6066675A (en) | 1996-09-13 | 2000-05-23 | The Regents Of The University Of California | Method for treatment of retinal diseases |
| CN1175904C (zh) | 1998-05-15 | 2004-11-17 | 若素制药株式会社 | 抗炎滴眼剂 |
| US6291466B1 (en) | 1998-07-30 | 2001-09-18 | Allergan Sales, Inc. | Cholinergic agents in the treatment of presbyopia |
| US6164282A (en) | 1999-01-27 | 2000-12-26 | Allergan Sales, Inc. | Methods for restoring and/or enhancing accommodation in pseudo phakia |
| US6420407B1 (en) | 1999-09-16 | 2002-07-16 | Gerald Horn | Ophthalmic formulation which modulates dilation |
| US6730065B1 (en) | 2000-09-15 | 2004-05-04 | Ocularis Pharma, Inc. | Night vision composition |
| AU7581000A (en) | 1999-09-16 | 2001-04-17 | Gerald D. Horn | A method for optimizing pupil size using alpha antagonist |
| WO2001037838A1 (en) | 1999-11-24 | 2001-05-31 | Wakamoto Pharmaceutical Co., Ltd. | Ophthalmic aqueous preparation |
| US6730691B1 (en) | 2000-02-10 | 2004-05-04 | Miles A. Galin | Uses of alpha adrenergic blocking agents |
| EP1299123A2 (en) * | 2000-07-13 | 2003-04-09 | Pharmacia Corporation | Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders |
| PE20020146A1 (es) | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
| US6273092B1 (en) | 2000-09-22 | 2001-08-14 | Gerard M. Nolan | Methods for treating various eye disorders |
| US6515006B2 (en) | 2000-11-08 | 2003-02-04 | Hmt Pharma, Inc. | Ophthalmic formulation which modulates dilation |
| US20050205101A1 (en) | 2002-10-17 | 2005-09-22 | Lin J T | Combined pharmocological and surgical method and system for the treatment of eye disorders |
| US20040078009A1 (en) | 2002-10-17 | 2004-04-22 | Lin J. T. | Method and apparatus for the treatment of presbyopia and other eye disorders combining pharmocological and surgical means |
| US20060177430A1 (en) | 2002-12-20 | 2006-08-10 | Chakshu Research Inc | Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer |
| US20050119262A1 (en) | 2003-08-21 | 2005-06-02 | Pharmacia Corporation | Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent |
| MXPA03011987A (es) | 2003-12-19 | 2005-06-23 | Osio Sancho Alberto | Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal. |
| WO2005099691A1 (en) * | 2004-03-31 | 2005-10-27 | Pharmacia & Upjohn Company Llc | Composition for treating elevated intraocular pressure |
| ATE439863T1 (de) | 2006-12-18 | 2009-09-15 | Jorge Luis Benozzi | Ophthalmische zusammensetzungen von parasympathischen stimulantia und entzündungshemmer zur verwendung bei der behandlung von presbyopie |
| GB0724558D0 (en) | 2007-12-15 | 2008-01-30 | Sharma Anant | Optical correction |
| TNSN08110A1 (en) | 2008-03-11 | 2009-07-14 | Rekik Raouf Dr | Drug delivery to the anterior and posterior segment of the eye from drops |
| CN102119120B (zh) * | 2008-08-08 | 2013-08-07 | 株式会社东芝 | 纳米碳生成装置 |
| CN102245166A (zh) * | 2008-10-21 | 2011-11-16 | 法姆莱特有限公司 | 作为雾的含溴莫尼定的组合物的眼部施用 |
| US20110091459A1 (en) | 2008-12-11 | 2011-04-21 | Auspex Pharmaceuticals, Inc. | Imidazole modulators of muscarinic acetylcholine receptor m3 |
| WO2010125416A1 (en) | 2009-04-27 | 2010-11-04 | Raouf Rekik | Drug delivery to the anterior and posterior segments of the eye |
| US20100298335A1 (en) | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and Methods for Ameliorating or Reducing Presbyopia |
| US8299079B2 (en) | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
| JP2012015266A (ja) | 2010-06-30 | 2012-01-19 | Sony Corp | 半導体光増幅器 |
| AR081049A1 (es) | 2010-08-17 | 2012-06-06 | Gonzalez Santos Alejandro Raul | Medicamento oftalmico para el tratamiento de la hipermetropia |
| TN2010000566A1 (en) | 2010-12-03 | 2012-05-24 | Rekik Raouf | Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs |
| CA2827373C (en) | 2011-02-15 | 2019-05-14 | Epi Health, Llc | Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea |
| US20120225918A1 (en) | 2011-03-03 | 2012-09-06 | Voom, Llc | Compositions and Methods for Non-Surgical Treatment of Ptosis |
| IN2014CN02961A (enExample) | 2011-09-20 | 2015-07-03 | Altavista Inst De Invest Medica S A S | |
| WO2013061161A2 (en) | 2011-10-28 | 2013-05-02 | Green Bcn Consulting Services Sl | New combination therapies for treating neurological disorders |
| US10507245B2 (en) | 2012-07-19 | 2019-12-17 | Luis Felipe Vejarano Restrepo | Ophthalmic formulation and method for ameliorating presbyopia |
| US9089562B2 (en) | 2013-08-28 | 2015-07-28 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| ES2538551B1 (es) | 2013-12-20 | 2016-01-13 | Eurocanarias Oftalmológica, Sl | Composición Oftálmica para la corrección de la presbicia |
-
2010
- 2010-08-18 IN IN2961CHN2014 patent/IN2014CN02961A/en unknown
-
2012
- 2012-09-19 MY MYPI2014000825A patent/MY168643A/en unknown
- 2012-09-19 US US14/129,012 patent/US9579308B2/en active Active
- 2012-09-19 CA CA3049795A patent/CA3049795A1/en not_active Abandoned
- 2012-09-19 CA CA2849366A patent/CA2849366C/en active Active
- 2012-09-19 JP JP2014531333A patent/JP6141850B2/ja not_active Expired - Fee Related
- 2012-09-19 UA UAA201404109A patent/UA113525C2/uk unknown
- 2012-09-19 MX MX2014003421A patent/MX357635B/es active IP Right Grant
- 2012-09-19 PH PH1/2014/500636A patent/PH12014500636B1/en unknown
- 2012-09-19 SG SG11201400828RA patent/SG11201400828RA/en unknown
- 2012-09-19 AU AU2012311239A patent/AU2012311239B2/en not_active Ceased
- 2012-09-19 EP EP23177574.3A patent/EP4272743A3/en not_active Withdrawn
- 2012-09-19 WO PCT/IB2012/002335 patent/WO2013041967A2/en not_active Ceased
- 2012-09-19 EP EP12813089.5A patent/EP2758047B1/en active Active
- 2012-09-19 ES ES12813089T patent/ES2715296T3/es active Active
- 2012-09-19 CN CN201280056271.8A patent/CN104093404B/zh not_active Expired - Fee Related
- 2012-09-19 DK DK12813089.5T patent/DK2758047T3/en active
- 2012-09-19 RU RU2014115439A patent/RU2630968C2/ru active
- 2012-09-19 TR TR2019/03465T patent/TR201903465T4/tr unknown
- 2012-09-19 BR BR112014006607A patent/BR112014006607A2/pt not_active Application Discontinuation
- 2012-09-19 KR KR1020147010384A patent/KR102017916B1/ko not_active Expired - Fee Related
- 2012-09-19 EP EP18211269.8A patent/EP3517111A3/en not_active Withdrawn
-
2013
- 2013-12-24 US US14/140,103 patent/US9301933B2/en active Active
-
2014
- 2014-03-20 ZA ZA2014/02049A patent/ZA201402049B/en unknown
- 2014-03-20 IL IL231631A patent/IL231631B/en active IP Right Grant
- 2014-03-20 CL CL2014000689A patent/CL2014000689A1/es unknown
- 2014-04-16 CO CO14083073A patent/CO7000769A2/es not_active Application Discontinuation
-
2016
- 2016-02-23 US US15/050,921 patent/US20160310466A1/en not_active Abandoned
-
2017
- 2017-10-05 AU AU2017239563A patent/AU2017239563B2/en not_active Ceased
- 2017-12-14 US US15/842,697 patent/US20180333392A1/en not_active Abandoned
-
2019
- 2019-04-04 US US16/375,499 patent/US20200069651A1/en not_active Abandoned
-
2021
- 2021-03-17 US US17/204,743 patent/US20220040152A1/en not_active Abandoned
-
2024
- 2024-05-15 US US18/665,291 patent/US20250049761A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014500636B1 (en) | Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism | |
| AR121843A2 (es) | Formulación oftálmica y método para mejorar la presbicia | |
| HK1258588A1 (zh) | 用於治疗眼科疾病的化合物和制剂 | |
| WO2012080497A3 (en) | Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases | |
| BR112014017650A8 (pt) | Uso de ésteres de forbol para tratar ou prevenir um ou mais dos sintomas da doença de parkinson | |
| MY183449A (en) | Formulations of quinones for the treatment of ophthalmic diseases | |
| CA2711696C (en) | Therapeutic compositions for treatment of ocular inflammatory disorders | |
| BR112015001847A2 (pt) | composições e tratamento para doenças e distúrbios nos olhos | |
| WO2012009171A3 (en) | Compositions and methods of treatment of corneal endothelium disorders | |
| EA200700109A1 (ru) | Способы лечения офтальмологических состояний (варианты) | |
| WO2012103186A3 (en) | Androgen composition for treating an opthalmic condition | |
| EA201291108A1 (ru) | Фармацевтические композиции в виде эмульсии с низким содержанием масла, содержащие прогестоген | |
| EA201490539A1 (ru) | Соединения и композиции в качестве ингибиторов c-kit киназы | |
| MA40768A (fr) | Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue | |
| MA40769A (fr) | Indoles mono ou di-substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue | |
| EP4324454A3 (en) | Cross-linking agents and associated methods | |
| MX2022008478A (es) | Combinaciones de brimonidina de dosis baja y usos de las mismas. | |
| EA201790397A1 (ru) | Композиции и способы для лечения нарушений зрения | |
| EA201001524A1 (ru) | Ингибиторы дезацетилазы в, основанные на гидроксамате | |
| WO2011116020A3 (en) | Ophthalmic formulations of cetirizine and methods of use | |
| WO2009114729A3 (en) | Compounds, compositions and methods for treating lysosomal storage diseases and disorders | |
| WO2013152193A3 (en) | Methods of treating proliferative disorders with malate or derivatives thereof | |
| EA201690532A1 (ru) | Не содержащий консерванта офтальмологический фармацевтический состав | |
| WO2013189606A3 (en) | Interval therapy for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases | |
| MX2022001069A (es) | Composiciones y metodos para el tratamiento de la presbicia. |